Operational Costs Compared: SG&A Analysis of GSK plc and Ascendis Pharma A/S

SG&A Expenses: GSK vs. Ascendis Pharma Over a Decade

__timestampAscendis Pharma A/SGSK plc
Wednesday, January 1, 201462740008246000000
Thursday, January 1, 201594150009232000000
Friday, January 1, 2016115040009366000000
Sunday, January 1, 2017134820009672000000
Monday, January 1, 2018250570009915000000
Tuesday, January 1, 20194847300011402000000
Wednesday, January 1, 20207666900011456000000
Friday, January 1, 202116018000010975000000
Saturday, January 1, 20222212270008372000000
Sunday, January 1, 20232644100009385000000
Monday, January 1, 2024284545000
Loading chart...

Infusing magic into the data realm

A Decade of SG&A: GSK plc vs. Ascendis Pharma A/S

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, GSK plc and Ascendis Pharma A/S have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. GSK, a stalwart in the industry, consistently reported SG&A expenses averaging around $9.8 billion annually, reflecting its expansive global operations. In contrast, Ascendis Pharma, a burgeoning biotech firm, saw its SG&A expenses skyrocket by over 4,000% from 2014 to 2023, highlighting its aggressive growth strategy.

By 2023, Ascendis Pharma's SG&A expenses reached approximately 2.6% of GSK's, a testament to its rapid expansion. This comparison underscores the diverse strategies employed by established giants and emerging innovators in managing operational costs. As the pharmaceutical sector continues to evolve, understanding these financial dynamics offers invaluable insights into corporate strategy and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025